GlassScriptPhysician profile
Marc S Zimmerman
NPI 1568543742
$1,989.39
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,974 · 2020: $15.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $182.71 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $169.60 | 2019 | |
| Amgen INC. | $167.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $158.64 | 2019 | |
| Merck Sharp & Dohme LLC | $151.03 | 2019 | |
| Octapharma USA, INC. | $102.76 | 2019 | |
| Eisai INC. | $93.18 | 2019 | |
| Genentech USA, INC. | $84.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $80.69 | 2019 | |
| Novocure INC. | $80.58 | 2019 | |
| Janssen Biotech, INC. | $57.65 | 2019 | |
| Tersera Therapeutics LLC | $54.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.81 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $48.80 | 2019 | |
| Amag Pharmaceuticals, INC. | $44.09 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $34.99 | 2019 | |
| Shire North American Group INC | $34.80 | 2019 | |
| Gilead Sciences, INC. | $31.58 | 2019 | |
| Celgene Corporation | $30.03 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.51 | 2019 | |
| Incyte Corporation | $27.02 | 2019 | |
| Agios Pharmaceuticals, INC. | $26.18 | 2019 | |
| Astellas Pharma US INC | $26.11 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.49 | 2019 | |
| Taiho Oncology, INC. | $21.39 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $18.07 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $17.87 | 2019 | |
| Medtronic USA, INC. | $17.62 | 2019 | |
| Lilly USA, LLC | $17.20 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.36 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.31 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.06 | 2019 | |
| Tesaro, INC. | $12.71 | 2019 | |
| Seagen INC. | $12.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Zimmerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.